person:elizabeth sackler

  • La famille Sackler, maître des opioïdes et amie des arts
    https://www.lemonde.fr/economie/article/2019/04/25/les-sackler-

    L’OxyContin, médicament hautement addictif, a fait la fortune de cette famille qui préfère parler de son mécénat plutôt que de sa responsabilité dans la crise sanitaire aux Etats-Unis.

    La cuillère a le fond calciné, et son manche est retourné pour lui donner plus de stabilité. Comme celles utilisées par les toxicomanes qui font fondre leur drogue. Sauf que l’ustensile pèse… près de 360 kg. Le 22 juin 2018, il bloquait l’entrée du siège de Purdue Pharma, à Stamford (Connecticut). La firme, propriété de la famille Sackler, produit l’OxyContin, puissant antidouleur fabriqué à partir de morphine de synthèse.

    Ce médicament a fait la fortune des Sackler, dont la richesse est estimée par l’agence Bloomberg à 13 milliards de dollars (11,6 milliards d’euros). Hautement addictif, il est surtout accusé d’avoir fait tomber dans la drogue des milliers d’Américains et d’être responsable de la crise des opioïdes qui frappe les Etats-Unis.
    L’OxyContin, commercialisé depuis 1995, aurait fait tomber dans la drogue des milliers d’Américains
    Depuis un an, l’artiste Domenic Esposito, 49 ans, mène une guérilla contre la famille Sackler avec sa cuillère. Il l’a de nouveau exposée le 5 avril à Washington, devant l’Agence américaine du médicament (FDA), à qui il est reproché d’avoir autorisé l’OxyContin. M. Esposito se bat pour son frère Danny, de dix-huit ans son cadet, qui a sombré dans la drogue au milieu des années 2000, en commençant par l’OxyContin, avant de se tourner vers l’héroïne.

    « Il a bousillé douze années de sa vie », confie Domenic Esposito, qui nous reçoit à Westwood, dans son atelier, en face de sa maison perdue dans les forêts du Massachusetts. Sa famille veut croire à une rémission, mais la désillusion n’est jamais loin. « Ma mère m’a souvent appelé en pleurant après avoir trouvé les résidus dans une cuillère, raconte-t-il. Cette cuillère est le symbole du combat macabre de ma famille. »

    Epidémie

    Ancien gestionnaire de capitaux reconverti dans l’art, M. Esposito a décidé de passer à l’action quand il s’est aperçu que son frère n’était pas un cas isolé.
    Le déclic s’est produit lors des journées de charité du diocèse de Boston, pendant le Carême de 2016. Catholique et bon orateur, il vante l’action du diocèse en faveur des victimes de la drogue. Et évoque son frère. Une fois son discours achevé, une dizaine de personnes viennent partager leur expérience. A chaque fois, le même scénario : une blessure banale mais nécessitant un antidouleur, et une ordonnance d’OxyContin. S’amorce alors l’engrenage de l’addiction avec, souvent, un basculement vers l’héroïne. Il s’agit bien d’une épidémie, provoquée par Purdue et les Sackler.
    Pourquoi ferrailler avec une œuvre d’art ? Parce que c’est là une des failles du clan. Si le nom de Purdue est peu connu, celui de la famille Sackler est, depuis un demi-siècle, synonyme de mécénat artistique. Au Metro­politan Museum (Met) et au Musée Guggenheim de New York, à la National Portrait Gallery de Londres ou au Louvre, à Paris, avec l’« aile ­Sackler des antiquités orientales », leur patronyme est omniprésent.


    Des personnes visitent l’aile Sackler au Metropolitan Museum of Art, à New York, le 28 mars.

    Puisque les Sackler s’abritent derrière les arts, les artistes veulent les faire périr par eux, comme le montre l’initiative de M. Esposito et comme le revendique la photographe américaine Nan Goldin, devenue dépendante à l’OxyContin après une opération. « Pour qu’ils nous écoutent, nous allons cibler leur philanthropie. Ils ont lavé leur argent maculé de sang grâce aux halls des musées et des uni­versités », accuse Mme Goldin, qui a photographié son propre calvaire.

    « Un blizzard d’ordonnances »

    En mars 2018, au Met, cinquante militants se sont allongés, feignant d’être morts, dans l’aile financée par les Sackler. En février 2019, au Musée Guggenheim, des activistes ont jeté de fausses ordonnances d’OxyContin, cruel rappel adressé à Richard Sackler, 74 ans, fils d’un des fondateurs et ex-PDG de Purdue, qui avait prédit « un blizzard d’ordonnances qui enterrerait la concurrence ».
    L’étau se resserre sur le front judiciaire, avec 1 600 plaintes déposées et des poursuites pénales engagées par les parquets de Boston et de New York

    Cela paie. En mars, le Guggenheim a fait savoir qu’il n’accepterait plus de dons de la famille, ­ tandis que Mortimer Sackler, ancien membre actif du conseil d’administration (CA) de Purdue et cousin de Richard, a dû se retirer du CA. A Londres, la Tate Gallery a fait de même, et la National Portrait Gallery a décliné une promesse de don de 1 million de livres (1,15 million d’euros).
    Parallèlement, l’étau se resserre sur le front judiciaire, avec 1 600 plaintes déposées et des poursuites pénales engagées par les parquets de Boston et de New York. Au point que la société pourrait déposer le bilan. Prolixes sur leurs activités philanthropiques et artistiques, les Sackler sont mutiques sur leur entreprise.


    La procureure générale de l’Etat de New York, Letitia James, annonce la plus importante poursuite en justice jamais intentée contre la famille Sackler, le 28 mars.

    L’histoire débute avec les trois frères Sackler, fils d’immigrants juifs de Galicie et de Pologne nés à Brooklyn. Tous trois médecins psychiatres, ils se lancent dans la pharmacie, en rachetant une petite entreprise de Greenwich Village, qui vend des produits comme la Betadine ou fait le marketing du Valium. Ils conquièrent des patients et, surtout, des médecins prescripteurs (en 1997, le patriarche, Arthur Sackler, a été distingué à titre posthume pour ses talents publicitaires).

    « Méthodes agressives »

    C’est cette recette qui, à partir de 1995, permet d’écouler l’OxyContin. A une époque où l’on cherche à apaiser les douleurs insupportables des malades du cancer, le produit apparaît comme une solution magique : il n’est pas addictif et soulage le patient pendant douze heures. Cela représente un formidable argument publicitaire, notamment parce qu’il se diffuse en continu.
    Cependant, au lieu d’être réservé aux patients en soins palliatifs, il est distribué comme de l’aspirine, à coups d’intéressement (pour les vendeurs) et de séminaires dans des palaces de Floride (pour les médecins). Les dosages très élevés créent une accoutumance mortifère. Les précieuses pilules, qui ont des qualités ­similaires à celles de l’héroïne lorsqu’elles sont brûlées, attirent l’attention des narcotrafiquants qui organisent un commerce de ­ contrebande très lucratif, avec la complicité de médecins véreux.

    Quand il apparaît que le produit est addictif, la firme choisit de ­blâmer les consommateurs. Dès 2003, l’Agence fédérale de ­contrôle des stupéfiants (DEA) l’accuse d’avoir, par ses « méthodes agressives », favorisé l’abus d’OxyContin et minimisé « les risques associés au médicament », raconte The New Yorker dans une enquête-fleuve publiée en octobre 2017 et intitulée « Un empire de douleur », qui estime à 35 milliards de dollars le chiffre d’affaires généré par le médicament.
    En 2007, Purdue accepte de verser 600 millions de dollars d’amende pour avoir prétendu que son médicament était moins addictif que ceux de ses concurrents. Trois ans plus tard, la firme élabore une nouvelle version de son produit, qui ne peut pas être transformée comme l’héroïne.

    Rumeurs de faillite

    Mais The New Yorker note qu’il s’agissait aussi de contrer l’arrivée de médicaments génériques, l’OxyContin devant tomber dans le domaine public en 2013. Et que l’effet paradoxal de l’affaire a été d’amplifier le basculement des drogués vers l’héroïne. « C’est un terrible paradoxe de l’histoire de l’OxyContin : la formule originelle a créé une génération accro aux pilules. Et sa reformulation (…) a créé une génération accro à l’héroïne. »
    L’Oklahoma, particulièrement touché, est parvenu fin mars à une transaction de 270 millions de dollars. Purdue préfère payer pour éviter un procès public et la publication de documents internes potentiellement désastreux. Des rumeurs de faillite courent, et certains Etats pourraient être tentés de conclure des transactions rapides plutôt que de ne rien obtenir.
    Pour d’autres, l’argent ne suffit pas. Il faut poursuivre les vrais coupables, et en premier lieu les Sackler. Les trois frères fondateurs sont morts, mais la famille, qui a touché 4,3 milliards de dollars de dividendes entre 2008 et 2016, dirige de facto la compagnie. Celle-ci ne s’exprime que par des communiqués laconiques, se disant soucieuse de « contribuer à lutter contre cette crise de santé publique complexe ».


    Des parents dénoncent la responsabilité de la famille Sackler dans la mort de leurs enfants, à Marlborough (Massachusetts), le 12 avril.

    Purdue répète qu’elle ne représente que 2 % des ventes d’opioïdes aux Etats-Unis, et ne peut être tenue, à elle seule, pour respon­sable de ladite crise. La procureure générale du Massachusetts, Maura Healey, ne s’en satisfait pas et a mis en examen huit membres de la famille impliqués dans l’entreprise. Elle s’appuie, entre autres, sur un courriel du patron de Purdue, Craig Landau, qui, selon la plainte, énonçait une évidence : « La famille dirigeait l’entreprise pharmaceutique mondiale Sackler et le conseil de surveillance jouait le rôle de PDG de facto. »

    « Les Sackler méritent la peine capitale »

    Les héritiers, qui estiment n’y être pour rien, se désolidarisent. C’est le cas des descendants du frère aîné et grand mécène Arthur, disparu en 1987 et dont les parts ont été récupérées non par ses enfants mais par ses frères. « Le rôle de Purdue [dans la crise des opioïdes] m’est odieux », a ainsi déclaré la fille d’Arthur, Elizabeth Sackler. Fondatrice d’un centre d’art féministe à Brooklyn, elle a aussi salué, dans le New York Times, « le courage de Nan Goldin ».
    Ses détracteurs ne l’entendent pas ainsi : ils estiment que ce sont les méthodes de marketing adoptées à partir des années 1950 par Arthur qui ont fait merveille pour l’OxyContin – méthodes auxquelles Purdue n’a renoncé que… début 2018. « Leur nom est terni pour toujours (…). Aujourd’hui, il y a des gens qui estiment que les Sackler méritent la peine capitale. Ils sont responsables de milliers de morts », accuse Domenic Esposito.
    Dans une manœuvre de sauve-qui-peut, les membres de la famille se retirent tous, depuis deux ans, du conseil d’administration de Purdue. Sans doute trop tard pour échapper aux poursuites de Mme Healey, à qui M. Esposito a offert sa cuillère militante.

  • The Arthur Sackler Family’s Ties to OxyContin Money - The Atlantic
    https://www.theatlantic.com/health/archive/2018/04/sacklers-oxycontin-opioids/557525

    Much as the role of the addictive multibillion-dollar painkiller OxyContin in the opioid crisis has stirred controversy and rancor nationwide, so it has divided members of the wealthy and philanthropic Sackler family, some of whom own the company that makes the drug.

    In recent months, as protesters have begun pressuring the Metropolitan Museum of Art in New York and other cultural institutions to spurn donations from the Sacklers, one branch of the family has moved aggressively to distance itself from OxyContin and its manufacturer, Purdue Pharma. The widow and one daughter of Arthur Sackler, who owned a related Purdue company with his two brothers, maintain that none of his heirs have profited from sales of the drug. The daughter, Elizabeth Sackler, told The New York Times in January that Purdue Pharma’s involvement in the opioid epidemic was “morally abhorrent to me.”

    But an obscure court document sheds a different light on family history—and on the campaign by Arthur’s relatives to preserve their image and legacy. It shows that the Purdue family of companies made a nearly $20 million payment to the estate of Arthur Sackler in 1997—two year after OxyContin was approved, and just as the pill was becoming a big seller. As a result, though they do not profit from present-day sales, Arthur’s heirs appear to have benefited at least indirectly from OxyContin.

    The 1997 payment to the estate of Arthur Sackler is disclosed in the combined, audited financial statements of Purdue and its associated companies and subsidiaries. Those documents were filed among hundreds of pages of exhibits in the U.S. District Court in Abingdon, Virginia, as part of a 2007 settlement in which a company associated with Purdue and three company executives pleaded guilty to charges that OxyContin was illegally marketed. The company paid $600 million in penalties while admitting it falsely promoted OxyContin as less addictive and less likely to be abused than other pain medications.

    Arthur’s heirs include his widow and grandchildren. His children, including Elizabeth, do not inherit because they are not beneficiaries of a trust that was set up as part of a settlement of his estate, according to court records. Jillian receives an income from the trust. Elizabeth’s two children are heirs and would receive bequests upon Jillian’s death. A spokesman for Elizabeth Sackler declined to comment on the Purdue payment.

    Long before OxyContin was introduced, the Sackler brothers already were notable philanthropists. Arthur was one of the world’s biggest art collectors and a generous benefactor to cultural and educational institutions across the world. There is the Arthur M. Sackler Gallery at the Smithsonian Institution, the Arthur M. Sackler Museum at Harvard, and the Jillian and Arthur M. Sackler Wing of Galleries at the Royal Academy of Arts in London.

    His brothers were similarly generous. They joined with their older brother to fund the Sackler Wing at the Met, which features the Temple of Dendur exhibit. The Mortimer and Theresa Sackler Foundation was the principal donor of the Serpentine Sackler Gallery in London; the Sackler name is affiliated with prestigious colleges from Yale to the University of Oxford, as well as world-famous cultural organizations, including the Victoria and Albert Museum in London. There is even a Sackler Rose—so christened after Mortimer Sackler’s wife purchased the naming rights in her husband’s honor.

    Now the goodwill gained from this philanthropy may be waning as the Sackler family has found itself in an uncomfortable spotlight over the past six months. Two national magazines recently examined the intersection of the family’s wealth from OxyContin and its philanthropy, as have other media outlets across the world. The family has also been targeted in a campaign by the photographer Nan Goldin to “hold the Sacklers accountable” for OxyContin’s role in the opioid crisis. Goldin, who says she became addicted to OxyContin after it was prescribed for surgical pain, led a protest last month at the Metropolitan Museum of Art, in which demonstrators tossed pill bottles labeled as OxyContin into the reflecting pool of its Sackler Wing.

    While it doesn’t appear that any recipients of Sackler charitable contributions have returned gifts or pledged to reject future ones, pressure and scrutiny on many of those institutions is intensifying. In London, the National Portrait Gallery said it is reviewing a current pledge from the Sackler Trust.

    #Opioides #Sackler

  • The #Opioid Timebomb: The #Sackler family and how their painkiller fortune helps bankroll London arts | London Evening Standard
    https://www.standard.co.uk/news/health/the-opioid-timebomb-the-sackler-family-and-how-their-painkiller-fortune-

    We sent all 33 non-profits the same key questions including: will they rename their public space (as some organisations have done when issues arose regarding former benefactors)? And will they accept future Sackler philanthropy?

    About half the respondents, including the Royal Opera House and the National Gallery, where Dame Theresa Sackler is respectively an honorary director and a patron, declined to answer either question.

    Of the rest, none said it planned to erase the Sackler name from its public space. The organisations’ positions were more guarded on future donations.

    Only the V&A, Oxford University, the Royal Court Theatre and the National Maritime Museum said outright that they were open to future Sackler grants.

    The V&A said: “The Sackler family continue to be a valuable donor to the V&A and we are grateful for their ongoing support.”

    Millions for London: Where Sackler money has gone
    MUSEUMS AND GALLERIES

    Serpentine Galleries

    Grants received/pledged: £5,500,000
    Used to fund (among other things): Serpentine Sackler Gallery
    Will you accept future Sackler grants? Won’t say

    Tate

    Grants received/pledged: £4,650,000
    Used to fund (among other things): Sackler Gallery, Sackler Escalators, Sackler Octagon
    Will you accept future Sackler grants? Won’t say

    Dulwich Picture Gallery

    Grants received/pledged: £3,491,000
    Used to fund (among other things): Sackler Centre for Arts Education
    Will you accept future Sackler grants? Won’t say

    V&A Museum

    Grants received/pledged: £2,500,000
    Used to fund (among other things): Sackler Courtyard
    Will you accept future Sackler grants? Yes

    The Design Museum

    Grants received/pledged: £1,500,000
    Used to fund (among other things): Sackler Library and Archive
    Will you accept future Sackler grants? No reply

    Natural History Museum

    Grants received/pledged: £1,255,000
    Used to fund (among other things): Sackler Biodiversity Imaging Laboratory
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    National Gallery

    Grants received/pledged: £1,050,000
    Used to fund (among other things): Sackler Room (Room 34)
    Will you accept future Sackler grants? Won’t say

    National Portrait Gallery

    Grants received/pledged: £1,000,000
    Used to fund (among other things): Pledged grant still being vetted
    Will you accept future Sackler grants? Being vetted. Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    The Garden Museum

    Grants received/pledged: £850,000
    Used to fund (among other things): Sackler Garden
    Will you accept future Sackler grants? No reply

    National Maritime Museum

    Grants received/pledged: £230,000
    Used to fund (among other things): Sackler Research Fellowships
    Will you accept future Sackler grants? Yes

    Museum of London

    Grants received/pledged: Refused to disclose grants received
    Used to fund (among other things): Sackler Hall
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    Royal Academy of Arts

    Grants received/pledged: Refused to disclose grants received
    Used to fund (among other things): Sackler Wing, Sackler Sculpture Gallery
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    THE PERFORMING ARTS

    Old Vic

    Grants received/pledged: £2,817,000
    Used to fund (among other things): Productions and projects
    Will you accept future Sackler grants? Won’t say

    Royal Opera House

    Grants received/pledged: £2,500,000
    Used to fund (among other things): Won’t say
    Will you accept future Sackler grants? Won’t say

    National Theatre

    Grants received/pledged: £2,000,000
    Used to fund (among other things): Sackler Pavilion
    Will you accept future Sackler grants? Won’t say

    Shakespeare’s Globe

    Grants received/pledged: £1,660,000
    Used to fund (among other things): Sackler Studios
    Will you accept future Sackler grants? Won’t say

    Royal Court Theatre

    Grants received/pledged: £360,000
    Used to fund (among other things): Sackler Trust Trainee Scheme
    Will you accept future Sackler grants? Yes

    UNIVERSITIES/RESEARCH

    University of Oxford

    Grants received/pledged: £11,000,000
    Used to fund (among other things): Bodleian Sackler Library, Keeper of Antiquities
    Will you accept future Sackler grants? Yes

    University of Sussex

    Grants received/pledged: £8,400,000
    Used to fund (among other things): Sackler Centre for Consciousness Science
    Will you accept future Sackler grants? Won’t say

    King’s College, London

    Grants received/pledged: £6,950,000
    Used to fund (among other things): Sackler Institute for Translational Neurodevelopment
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    The Francis Crick Institute

    Grants received/pledged: £5,000,000
    Used to fund (among other things): One-off funds raised via CRUK to help build the Crick
    Will you accept future Sackler grants? N/A

    UCL

    Grants received/pledged: £2,654,000
    Used to fund (among other things): Sackler Institute for Musculo-Skeletal Research
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    Royal College of Art

    Grants received/pledged: £2,500,000
    Used to fund (among other things): Sackler Building
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    The Courtauld Institute of Art

    Grants received/pledged: £1,170,000
    Used to fund (among other things): Sackler Research Fellowship, Sackler Lecture Series
    Will you accept future Sackler grants? Won’t say

    Royal Ballet School

    Grants received/pledged: £1,000,000
    Used to fund (among other things): Won’t say
    Will you accept future Sackler grants? Won’t say

    Imperial College London

    Grants received/pledged: £618,000
    Used to fund (among other things): Knee research
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    Old Royal Naval College

    Grants received/pledged: £500,000
    Used to fund (among other things): Sackler Gallery
    Will you accept future Sackler grants? Won’t say

    OTHER

    Royal Botanic Gardens, Kew

    Grants received/pledged: £3,100,000
    Used to fund (among other things): Sackler Crossing footbridge
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    Moorfields Eye Hospital

    Grants received/pledged: £3,000,000
    Used to fund (among other things): New eye centre (pledged only)
    Will you accept future Sackler grants? Won’t say

    The London Library

    Grants received/pledged: £1,000,000
    Used to fund (among other things): The Sackler Study
    Will you accept future Sackler grants? Won’t say

    The Prince’s Trust

    Grants received/pledged: £775,000
    Used to fund (among other things): Programmes for disadvantaged youth
    Will you accept future Sackler grants? Subject to vetting that typically takes into account “reputational risk” and “all relevant new information about the donor in the public domain”

    Westminster Abbey

    Grants received/pledged: £500,000
    Used to fund (among other things): Restoration of Henry VII Chapel
    Will you accept future Sackler grants? Won’t say

    Royal Hospital for Neurodisability

    Grants received/pledged: £350,000
    Used to fund (among other things): Won’t say
    Will you accept future Sackler grants? No reply

    cc @hlc

    • Rob Reich, an ethics professor at Stanford University, has said that non-profits taking future Sackler donations could be seen as being “complicit in the reputation-laundering of the donor”.

      La liste ci dessus ne concerne que la GB mais en France la liste doit être longue aussi et encore plus aux USA et probablement un peu partout dans le monde.

      But our FoI requests revealed that at least one major Sackler donation has been held up in the vetting process: namely a £1 million grant for the National Portrait Gallery.

      The gallery said: “The Sackler Trust pledged a £1 million grant in June 2016 for a future project, but no funds have been received as this is still being vetted as part of our internal review process.

      Each gift is assessed on a case-by-case basis and where necessary, further information and advice is sought from third parties.”

      It added that its ethical fundraising policy sets out “unacceptable sources of funding” and examines the risk involved in “accepting support which may cause significant potential damage to the gallery’s reputation”.

    • What do the Sacklers say in their defence? The three brothers who founded Purdue in the Fifties — Arthur, Mortimer and Raymond — are dead but their descendants have conflicting views.

      Arthur’s daughter Elizabeth Sackler, 70, said her side of the family had not benefited a jot from OxyContin, which was invented after they were bought out in the wake of her father’s death in 1987. She has called the OxyContin fortune “morally abhorrent”.

      Her stepmother, British-born Jillian Sackler, who lives in New York and is a trustee at the Royal Academy of Arts, has called on the other branches of the family to acknowledge their “moral duty to help make this right and to atone for mistakes made”.

      But the OxyContin-rich branches of the family have remained silent. Representatives of Mortimer’s branch — the London Sacklers — said nobody was willing to speak on their behalf and referred us to Purdue’s communications director, Robert Josephson. He confirmed that the US-based Sacklers — Raymond’s branch — would not speak to us either, but that a Purdue spokesman would answer our questions.

      We asked the Purdue spokesman: does Purdue, and by extension the Sacklers, acknowledge the opioid crisis and a role in it?

      “Absolutely we acknowledge there is an opioid crisis,” he said, from Purdue’s HQ in Stamford, Connecticut. “But what’s driving the deaths is illicitly manufactured #fentanyl from China. It’s extremely potent and mixed with all sorts of stuff.”

      –—

      Philip Hopwood, 56, whose addiction to OxyContin and other opioids destroyed his £3 million business and his marriage, said: “If the Sackler family had a shred of decency, they would divert their philanthropy to help people addicted to the drugs they continue to make their fortune from.

      “The non-profits should be ashamed. At the very least they should be honest about the source of their funds.

      The V&A should rename their courtyard the OxyContin Courtyard and the Serpentine should call their gallery the OxyContin Gallery.

      “The money that built these public spaces comes from a drug that is killing people and ruining lives. They can no longer turn a blind eye. I’d feel sick to walk into a Sackler-named space.”

  • In the Discussion About the Sacklers and Oxycontin, It’s Important to Get the Facts Right | artnet News
    https://news.artnet.com/opinion/discussion-sacklers-oxycontin-facts-elizabeth-a-sackler-1203458

    Some of the many media articles about the family, such as Christopher Glazek’s piece in Esquire, have drawn the correct distinction between Elizabeth Sackler and her father Arthur M. Sackler—who have never been involved in nor benefited from the sale of Oxycontin—and other branches of the Sackler family, who have been involved in and benefited directly from this harmful drug through their company Purdue Pharma.

    Se foutre de la gueule du monde : Et la publicité Valium et la crise de dépendance qui s’en est suivie ? C’est par Arthur peut-être ? Et MS Contin ?

    #Opioides #Sackler

    • @madmeg : Elizabeth, la fille d’Arthur Sackler prétend ne jamais avoir touché de l’argent lié à OxyContin, ce qui est vrai... l’entreprise ayant été revenue à ses oncles au décès de son père. Mais elle a touché les royalties provenant de la publicité du Valium et sur la première version MS Contin de cette soi-disant formulation qui ne rend pas accro (cette fois, c’était avec de la morphine, quand OxyContin est avec de l’oxycodone, plus facile à fabriquer (synthétique) et plus puissante. On ne sait pas pour les autres entreprises satellites de la famille (I.M.S., Mundi-Pharma,...).

  • The Arthur Sackler Family’s Ties to OxyContin Money - The Atlantic
    https://www.theatlantic.com/health/archive/2018/04/sacklers-oxycontin-opioids/557525

    In recent months, as protesters have begun pressuring the Metropolitan Museum of Art in New York and other cultural institutions to spurn donations from the Sacklers, one branch of the family has moved aggressively to distance itself from OxyContin and its manufacturer, Purdue Pharma. The widow and one daughter of Arthur Sackler, who owned a related Purdue company with his two brothers, maintain that none of his heirs have profited from sales of the drug. The daughter, Elizabeth Sackler, told The New York Times in January that Purdue Pharma’s involvement in the opioid epidemic was “morally abhorrent to me.”

    Arthur died eight years before OxyContin hit the marketplace. His widow, Jillian Sackler, and Elizabeth, who is Jillian’s stepdaughter, are represented by separate public-relations firms and have successfully won clarifications and corrections from media outlets for suggesting that sales of the potent opioid enriched Arthur Sackler or his family.

    But an obscure court document sheds a different light on family history—and on the campaign by Arthur’s relatives to preserve their image and legacy. It shows that the Purdue family of companies made a nearly $20 million payment to the estate of Arthur Sackler in 1997—two year after OxyContin was approved, and just as the pill was becoming a big seller. As a result, though they do not profit from present-day sales, Arthur’s heirs appear to have benefited at least indirectly from OxyContin.

    The 1997 payment to the estate of Arthur Sackler is disclosed in the combined, audited financial statements of Purdue and its associated companies and subsidiaries. Those documents were filed among hundreds of pages of exhibits in the U.S. District Court in Abingdon, Virginia, as part of a 2007 settlement in which a company associated with Purdue and three company executives pleaded guilty to charges that OxyContin was illegally marketed. The company paid $600 million in penalties while admitting it falsely promoted OxyContin as less addictive and less likely to be abused than other pain medications.

    Long before OxyContin was introduced, the Sackler brothers already were notable philanthropists. Arthur was one of the world’s biggest art collectors and a generous benefactor to cultural and educational institutions across the world. There is the Arthur M. Sackler Gallery at the Smithsonian Institution, the Arthur M. Sackler Museum at Harvard, and the Jillian and Arthur M. Sackler Wing of Galleries at the Royal Academy of Arts in London.

    His brothers were similarly generous. They joined with their older brother to fund the Sackler Wing at the Met, which features the Temple of Dendur exhibit. The Mortimer and Theresa Sackler Foundation was the principal donor of the Serpentine Sackler Gallery in London; the Sackler name is affiliated with prestigious colleges from Yale to the University of Oxford, as well as world-famous cultural organizations, including the Victoria and Albert Museum in London. There is even a Sackler Rose—so christened after Mortimer Sackler’s wife purchased the naming rights in her husband’s honor.

    Now the goodwill gained from this philanthropy may be waning as the Sackler family has found itself in an uncomfortable spotlight over the past six months. Two national magazines recently examined the intersection of the family’s wealth from OxyContin and its philanthropy, as have other media outlets across the world. The family has also been targeted in a campaign by the photographer Nan Goldin to “hold the Sacklers accountable” for OxyContin’s role in the opioid crisis. Goldin, who says she became addicted to OxyContin after it was prescribed for surgical pain, led a protest last month at the Metropolitan Museum of Art, in which demonstrators tossed pill bottles labeled as OxyContin into the reflecting pool of its Sackler Wing.

    While it doesn’t appear that any recipients of Sackler charitable contributions have returned gifts or pledged to reject future ones, pressure and scrutiny on many of those institutions is intensifying. In London, the National Portrait Gallery said it is reviewing a current pledge from the Sackler Trust.

    #Opioids #Sackler